The roles of PON1 and PON2 in cardiovascular disease and innate immunity

Current Opinion in Lipidology

Volumn 20, Issue 4, 2009, Pages 288-292

  Shih, Diana M ^a   Lusis, Aldons J ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Human Genetics ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; HDL; Oxidative stress; Paraoxonases; Quorum sensing

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; DIACYLGLYCEROL ACYLTRANSFERASE 1;

APOPTOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; GENOTYPE; HUMAN; INNATE IMMUNITY; LETHALITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW;

ANIMALS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR DISEASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNITY, INNATE;

PSEUDOMONAS AERUGINOSA;

EID: 68449096849     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32832ca1ee     Document Type: Review

References (34)

1. Hassett C, Richter RJ, Humbert R, et al. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 1991; 30:10141-10149.
2. Blatter MC, James RW, Messmer S, et al. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 1993; 211:871-879.
3. Reddy ST, Wadleigh DJ, Grijalva V, et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 2001; 21:542-547.
4. Shamir R, Hartman C, Karry R, et al. Paraoxonases (PONs) 1, 2, and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line: selective secretion of PON1 and PON2. Free Radic Biol Med 2005; 39:336-344.
5. Ng CJ, Wadleigh DJ, Gangopadhyay A, et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001; 276:44444-44449.
6. Horke S, Witte I, Wilgenbus P, et al. Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation 2007; 115:2055-2064.
7. Draganov DI, Teiber JF, Speelman A, et al. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005; 46:1239-1247.
8. Ozer EA, Pezzulo A, Shih DM, et al. Human and murine paraoxonase 1 are host modulators of Pseudomonas aeruginosa quorum-sensing. FEMS Microbiol Lett 2005; 253:29-37.
9. Yang F, Wang LH, Wang J, et al. Quorum quenching enzyme activity is widely conserved in the sera of mammalian species. FEBS Lett 2005; 579:3713-3717.
10. Lusis AJ. Atherosclerosis. Nature 2000; 407:233-241.
11. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286:152-154.
12. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96:2882-2891.
13. Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101:1581-1590.
14. Jarvik GP, Rozek LS, Brophy VH, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 2000; 20:2441-2447.
15. Mackness B, Durrington P, McElduff P, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003; 107:2775-2779.
16. Wheeler JG, Keavney BD, Watkins H, et al. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004; 363:689-695.
17. Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394:284-287.
18. Shih DM, Xia YR, Wang XP, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000; 275:17527-17535.
19. Tward A, Xia YR, Wang XP, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106:484-490.
20. Ng CJ, Shih DM, Hama SY, et al. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 2005; 38:153-163.
21. Ng CJ, Bourquard N, Grijalva V, et al. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: antiatherogenic role for paraoxonase-2. J Biol Chem 2006; 281: 29491-29500.
22. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008; 299:1265-1276..
23. Bauters C, Amant C, Boullier A, et al. Paraoxonase polymorphism (Gln192Arg) as a determinant of the response of human coronary arteries to serotonin. Circulation 2000; 101:740-743.
24. Pasqualini L, Cortese C, Marchesi S, et al. Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 2005; 183:349-354.
25. Lavi S, McConnell JP, Lavi R, et al. Association between the paraoxonase-1192Q>R allelic variant and coronary endothelial dysfunction in patients with early coronary artery disease. Mayo Clin Proc 2008; 83: 158-164.
26. Giusti B, Saracini C, Bolli P, et al. Genetic analysis of 56 polymorphisms in 17 genes involved in methionine metabolism in patients with abdominal aortic aneurysm. J Med Genet 2008; 45:721-730.
27. McCormick ML, Gavrila D, Weintraub NL. Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2007; 27:461-469.
28. Jaichander P, Selvarajan K, Garelnabi M, Parthasarathy S. Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res 2008; 49:2142-2148.
29. Fortunato G, Di Taranto MD, Bracale UM, et al. Decreased paraoxonase-2 expression in human carotids during the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28:594-600.
30. Horke S, Witte I, Wilgenbus P, et al. Protective effect of paraoxonase-2 against endoplasmic reticulum stress-induced apoptosis is lost upon disturbance of calcium homoeostasis. Biochem J 2008; 416:395-405.
31. Rosenblat M, Coleman R, Reddy ST, Aviram M. Paraoxonase 2 (PON2) attenuates macrophage triglyceride accumulation via inhibition of diacylglycerol acyltransferase 1 (DGAT1), the rate limiting enzyme in triglycerides biosynthesis. J Lipid Res 2009; 50:870-879.
32. Teiber JF, Horke S, Haines DC, et al. Dominant role of paraoxonases in inactivation of the Pseudomonas aeruginosa quorum-sensing signal N-(3-oxododecanoyl)-L-homoserine lactone. Infect Immun 2008; 76:2512-2519.
33. Stoltz DA, Ozer EA, Ng CJ, et al. Paraoxonase-2 deficiency enhances Pseudomonas aeruginosa quorum sensing in murine tracheal epithelia. Am J Physiol Lung Cell Mol Physiol 2007; 292:L852-L860.
34. Stoltz DA, Ozer EA, Taft PJ, et al. Drosophila are protected from Pseudomonas aeruginosa lethality by transgenic expression of paraoxonase-1. J Clin Invest 2008; 118:3123-3131.